Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q1 2016 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Apr 29, 2016

  1. Slide 1: First Quarter 2016 Operational and Financial Results

    First Quarter 2016 Operational and Financial Results Nasdaq: NLNK April 29, 2016

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO 2016 Priorities  Charles J. Link, Jr., M.D., Chairman, CEO & CSO IDO Pathway Inhibitor Programs Update  Nicholas N. Vahanian, M.D., President & CMO GDC-0919 Update  Dr. Vahanian First Quarter 2016 Financial Results  Mr. Hennem

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Priv

  4. Slide 4: NewLink Genetics Programs

    4 NewLink Genetics Programs HyperAcute® Cellular Immunotherapies  Pancreatic  NSCLC  Advanced Melanoma  Prostate  Kidney IDO Pathway Inhibitors  Breast  Prostate  Pancreatic  Advanced Melanoma  Refractory Malignant Brain Tumors  Solid Tumors Infectious Diseases Ebola vaccine program Zika

  5. Slide 5: 2016 Business Priorities

    2016 Business Priorities 5 Charles J. Link, Jr., M.D., Chairman, CEO, & CSO HyperAcute Cellular Immunotherapy  IMPRESS Phase 3 – Report on top-line results in 2Q-2016 – Execute on regulatory strategy with FDA – Continue U.S. commercialization planning – Explore partnering strategy outside U.S.  Hy

  6. Slide 6: IDO Pathway Inhibitor Programs Update

    IDO Pathway Inhibitor Programs Update 6 Nicholas Vahanian, M.D., President & Chief Medical Officer IDO Pathway Inhibitors  Provide clinical update at ASCO in June 2016 on the following trials: – Interim data update from a Phase 2 trial with a target enrollment of 80 patients evaluating the addition

  7. Slide 7: IDO Pathway Inhibitor Programs Update

    IDO Pathway Inhibitor Programs Update 7 Nicholas Vahanian, M.D., President & Chief Medical Officer IDO Pathway Inhibitors  Additional data updates expected in Q2 2016 include: – Mid-trial from a Phase 2 trial with a target enrollment of 132 patients of indoximod in combination with temozolomide for

  8. Slide 8: GDC-0919 Clinical Update

    GDC-0919 Clinical Update 8 Nicholas Vahanian, M.D., President & Chief Medical Officer GDC-0919: Partnered with Genentech  Genentech to present an update on GDC-0919 at ESMO in October

  9. Slide 9: First Quarter 2016 Financial Results

    First Quarter 2016 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position  Stable and reliable cash position - $178M at Q1 2016 / $197.8M at YE 2015  Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Increased Investment 

  10. Slide 10: Brewin

    Brewin A

NewLink Genetics — Q1 2016 Earnings Presentation on 6ix